Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Beta Bionics, Inc.NASDAQ: BBNX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 14.0% from a year ago
Other current liabilities stood at $8.34M at the end of Q1 FY2026, up 14.0% from a year earlier and down 42.8% from the prior quarter. Over 3 fiscal years it compounded at +122.5% a year.
Context
- Other current liabilities amounted to 2.7% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +14.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 14.59M USD
- Year-over-year change
- +33.4%
- 3-year CAGR
- +122.5%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.59M | +33.4% |
| FY2024 | 2024-12-31 | 10.94M | +858.5% |
| FY2023 | 2023-12-31 | 1.14M | -13.8% |
| FY2022 | 2022-12-31 | 1.32M | — |
Other Current Liabilities vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.0% is the 4th highest of 7, against a peer median of +60.2%.
- Other current liabilities amounts to 2.7% of total assets for BBNX, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 45.5B DKK | -69.8% | +21.9% | 7.6% | |
| Jun 2026 | $1.9B USD | +3302.7% | +4.6% | 29.5% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $488M USD | — | — | 10.3% |
| Mar 2026 | $139.8M USD | -1.7% | +28.9% | 12.1% | |
| Mar 2026 | $64.98M USD | +122.2% | +61.9% | 8.7% | |
| Mar 2026 | $8.34M USD | +14.0% | +122.5% | 2.7% | |
| Mar 2026 | $3.23M USD | +286.1% | — | 1.2% | |
| Jun 2026 | $0 USD | -100.0% | +23.5% | 0.0% | |
| Peer median (excluding BBNX) | — | +60.2% | +23.5% | 8.7% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.